Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients |
Kim, Tae-Hoon
(Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine)
Kim, Byung-Gyu (Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine) Cho, Sung-Woo (Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine) Cho, Sung-Kyun (Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine) Kim, Hyun-Jung (Departments of Pathology, Sanggye-Paik Hospital, Inje University College of Medicine) Yuh, Young-Jin (Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine) Kim, Sung-Rok (Departments of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine) |
1 | Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21: 3171-3. DOI |
2 | Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941-2. DOI ScienceOn |
3 | Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59: 423-6. |
4 | Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56. DOI ScienceOn |
5 | Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-75. DOI ScienceOn |
6 | Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96: 3343-56. |
7 | Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53. DOI ScienceOn |
8 | Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009;84:287-93. DOI ScienceOn |
9 | Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7. DOI ScienceOn |
10 | Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-9. DOI ScienceOn |
11 | Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4. DOI ScienceOn |